Trump’s Beijing blind spots: The two glaring holes in his war on high drug prices

President Donald Trump’s drug pricing policy has two China blind spots. The first is that Washington is pressing other developed economies to pay what it calls their fair share for pharmaceutical innovation, while China remains largely outside that burden-sharing effort, even as Chinese drug developers increasingly benefit from the high-priced American market through licensing and […]

Read it at Washington Examiner ↗

← Front page